EMD-27754

Single-particle
3.25 Å
EMD-27754 Deposition: 01/08/2022
Map released: 02/11/2022
Last modified: 30/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-27754

CryoEM structure of Gq-coupled MRGPRX1 with ligand Compound-16

EMD-27754

Single-particle
3.25 Å
EMD-27754 Deposition: 01/08/2022
Map released: 02/11/2022
Last modified: 30/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Homo sapiens
Sample: MRGPRX1-Gq BAM8-22
Fitted models: 8dwh (Avg. Q-score: 0.51)
Raw data: EMPIAR-11191, EMPIAR-11188

Deposition Authors: Liu Y , Cao C , Fay JF , Roth BL
Ligand recognition and allosteric modulation of the human MRGPRX1 receptor.
Liu Y , Cao C , Huang XP, Gumpper RH, Rachman MM , Shih SL , Krumm BE , Zhang S , Shoichet BK , Fay JF , Roth BL
(2023) Nat Chem Biol , 19 , 416 - 422
PUBMED: 36302898
DOI: doi:10.1038/s41589-022-01173-6
ISSN: 1552-4469
Abstract:
The human MAS-related G protein-coupled receptor X1 (MRGPRX1) is preferentially expressed in the small-diameter primary sensory neurons and involved in the mediation of nociception and pruritus. Central activation of MRGPRX1 by the endogenous opioid peptide fragment BAM8-22 and its positive allosteric modulator ML382 has been shown to effectively inhibit persistent pain, making MRGPRX1 a promising target for non-opioid pain treatment. However, the activation mechanism of MRGPRX1 is still largely unknown. Here we report three high-resolution cryogenic electron microscopy structures of MRGPRX1-Gαq in complex with BAM8-22 alone, with BAM8-22 and ML382 simultaneously as well as with a synthetic agonist compound-16. These structures reveal the agonist binding mode for MRGPRX1 and illuminate the structural requirements for positive allosteric modulation. Collectively, our findings provide a molecular understanding of the activation and allosteric modulation of the MRGPRX1 receptor, which could facilitate the structure-based design of non-opioid pain-relieving drugs.